OV - First prostate cancer patient included in Oncology Venture´s Phase 2 study of Irofulven for personalized treatment
(WorldNews Denmark)

Hoersholm, Denmark,October 18, 2018- Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) announces the inclusion of the first patient in a Phase 2 study of Irofulven - a drug candidate that exploits cancer cells` deficiency in DNA repair mechanisms. Irofulven has demonstrated effect in Prostate cancer and the objective of the study, which is expected to enroll a total of 13-27 patients. The aim is to demonstrate the strength of our response prediction technology and increase the efficacy of Irofulven to provide a new treatment of prostate cancer. During the screening and inclusion process,Oncology Venture`s Drug Response Predictor - DRP®- is used to Track, Match and thereby to decide...